SCHEMBL6893338

SCHEMBL6893338

COc1cccc(-c2cnn3c(N)cc(C4CCC(C(=O)O)NC4)nc23)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 13/20 0.53
CCNA2 P20248 10/20 0.53
CDK2 P24941 10/20 0.53
CCNA1 P78396 10/20 0.53
PIM1 P11309 1/20 0.42
NEK2 P51955 1/20 0.42
PLAT P00750 1/20 0.42
PIK3CA P42336 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894338 0.91 CHEK1 (0.52) CHEK1CCNA2CDK2CCNA1PLAT
SCHEMBL6893401 0.87 CHEK1 (0.49) CHEK1CCNA2CDK2CCNA1NEK2
SCHEMBL6893629 0.87 CHEK1 (0.63) CHEK1CCNA2CDK2CCNA1HSD17B10
SCHEMBL6894206 0.86 CHEK1 (0.56) CHEK1CCNA2CDK2CCNA1HSD17B10
SCHEMBL6893627 0.86 CHEK1 (0.55) CHEK1CCNA2CDK2CCNA1PIM1
SCHEMBL6894626 0.86 CHEK1 (0.48) CHEK1CCNA2CDK2CCNA1PIK3CA
SCHEMBL6893351 0.86 CHEK1 (0.47) CHEK1CCNA2CDK2CCNA1
SCHEMBL6891587 0.85 CHEK1 (0.49) CHEK1CCNA2CDK2CCNA1PLAT
SCHEMBL7875819 0.85 CHEK1 (0.55) CHEK1CCNA2CDK2CCNA1PLAT
SCHEMBL6894265 0.85 CHEK1 (0.53) CHEK1CCNA2CDK2CCNA1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CHEK1 2755/4885CCNA2 2265/4885CDK2 457/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.